Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00643) | |||||
---|---|---|---|---|---|
Name |
Sulfasalazine
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
sulfasalazine; 599-79-1; Azulfidine; Salicylazosulfapyridine; Salazosulfapyridine; Sulphasalazine; Salazopyrin; Asulfidine; Salazopyridin; Accucol; Azopyrin; Sulcolon; Colo-Pleon; Salazopiridazin; Azopyrine; Benzosulfa; Reupirin; Salisulf; Salazosulfapyridin; w-t Sasp oral; Sulfasalazin; Azulfidine EN; Sulfasalazina; Sulfasalazinum; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Salazosulfapyridinum; Sas-500; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; S.A.S.-500; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; NSC 667219; CHEBI:9334; NSC 203730; S.A.S. 500; C18H14N4O5S; UNII-3XC8GUZ6CB; 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic Acid; Benzoic acid, 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]-; (E)-2-hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; MFCD00057363; 3XC8GUZ6CB; Sulfasalazine (Azulfidine); CHEMBL421; Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)-; S.A.S.; Azosulfidin; 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 5-[p-(2-Pyridylsulfamoyl)phenylazo]salicylic acid; Sulfasalazine-d4; 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID; NSC203730; NSC667219; NSC-203730; NSC-667219; Salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)-; NCGC00090903-01; Salazo-sulfapyridinum; CAS-599-79-1; 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid; DSSTox_CID_1256; 2-hydroxy-5-[(E)-{4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl]benzoic acid; DSSTox_RID_76043; 5-[p-(2-Pyridylsulfamyl)phenylazo]salicylic acid; DSSTox_GSID_21256; Q63398427; Sulfasalazinum [INN-Latin]; Sulfasalazina [INN-Spanish]; Salicylic acid, 5-[[p-(2-pyridylsulfamoyl)phenyl]azo]-; 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid; Salazosulfapyridinum [INN-Latin]; 2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid; Salazosulfapiridina [INN-Spanish]; 2-Hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid; Azulfidine (TN); SMR000059146; Sulphasalazine, N-; CCRIS 4713; HSDB 3395; 5-(p-(2-Pyridylsulfamoyl)phenylazo)salicylic acid; SR-05000001721; EINECS 209-974-3; 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; Sulfasalazine (USP/INN); BRN 0356241; 2-hydroxy-5-({4-[(2-pyridylamino)sulfonyl]phenyl}diazenyl)benzoic acid; Prestwick_848; Sulfasalazine [USAN:USP:INN:BAN]; Spectrum_000998; Prestwick0_000520; Prestwick1_000520; Prestwick2_000520; Prestwick3_000520; Spectrum2_001216; Spectrum3_001364; Spectrum4_000347; Spectrum5_001443; Epitope ID:122672; SCHEMBL4514; SCHEMBL4515; Salazosulfapyridine (JP17); SCHEMBL18490; BSPBio_000479; BSPBio_002888; KBioGR_000753; KBioGR_002314; KBioSS_001478; KBioSS_002316; 5-22-08-00433 (Beilstein Handbook Reference); MLS000759399; MLS001424109; MLS006011702; BIDD:GT0161; DivK1c_000860; SPECTRUM1500552; SPBio_001032; SPBio_002400; BPBio1_000527; CHEMBL100848; CHEMBL242373; GTPL4840; SCHEMBL1079598; SCHEMBL1229516; CHEMBL1206016; DTXSID0021256; SCHEMBL10289061; CHEBI:94500; HMS502K22; KBio1_000860; KBio2_001478; KBio2_002314; KBio2_004046; KBio2_004882; KBio2_006614; KBio2_007450; KBio3_002108; KBio3_002794; cMAP_000018; NINDS_000860; HMS1569H21; HMS1921C05; HMS2051J21; HMS2090P13; HMS2092K07; HMS2096H21; HMS2232H07; HMS3370D16; HMS3393J21; HMS3655G07; HMS3713H21; HMS3871J13; HMS3884E21; Pharmakon1600-01500552; ALBB-033361; BCP13311; ZINC3831490; Tox21_111037; Tox21_201239; Tox21_300541; ANW-43676; BDBM50097125; BDBM50103596; CCG-39145; DL-510; KM0360; NSC757330; SBB058178; ZINC14768602; ZINC85550135; AKOS002311709; AKOS025116975; AKOS026749974; Tox21_111037_1; WLN: T6NJ BSWMR DNUNR DQ CVQ; ZINC100030102; ZINC100031653; CCG-100987; DB00795; HS-0062; MCULE-7533021815; NC00237; NSC-757330; VA11798; IDI1_000860; SMP2_000059; NCGC00016518-01; NCGC00090903-02; NCGC00090903-03; NCGC00090903-04; NCGC00090903-05; NCGC00090903-06; NCGC00090903-07; NCGC00090903-08; NCGC00090903-09; NCGC00090903-11; NCGC00186644-01; NCGC00254313-01; NCGC00258791-01; AC-20497; AK163126; HY-14655; SMR004703430; SY052318; SBI-0051526.P003; AB0013330; DB-017797; FT-0603483; FT-0674746; ST50767935; SW196979-4; C07316; D00448; J10488; AB00052101-04; AB00052101-06; AB00052101_07; AB00052101_08; 599S791; Q420035; Q-201769; SR-05000001721-1; SR-05000001721-2; SR-05000001721-3; Sulfasalazine, analytical standard, >=98% (HPLC); 5-[[4-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; BRD-K10670311-001-06-4; BRD-K10670311-001-08-0; Q27166356; Sulphasalazine, Antibiotic for Culture Media Use Only; F2173-1125; Z2030502809; 4-(Pyridyl-2-amidosulfonyl)-3''-carboxy-4''-hydroxyazobenzene; Sulfasalazine, European Pharmacopoeia (EP) Reference Standard; 2-hydroxy-5-[(E)-[4-(2-pyridylsulfamoyl)phenyl]azo]benzoic acid; 5-{4-[(2-pyridylideneamino)sulfonyl]phenyldiazenyl}salicylic acid; Sulfasalazine, United States Pharmacopeia (USP) Reference Standard; (E)-2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-Hydroxy-5-((4-[(2-pyridinylamino)sulfonyl]phenyl)diazenyl)benzoic acid #; 2-hydroxy-5-{(E)-[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid; 737754-28-8
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Rheumatoid arthritis | ICD-11: FA20 | [1] | ||
PubChem CID | |||||
Formula |
C18H14N4O5S
|
||||
Canonical SMILES |
C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
|
||||
InChI |
1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)
|
||||
InChIKey |
NCEXYHBECQHGNR-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5339"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 398.4 | Topological Polar Surface Area | 150 | |
XlogP | -0.7 | Complexity | 657 | ||
Heavy Atom Count | 28 | Rotatable Bond Count | 6 | ||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 9 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Sulfasalazine 500 mg tablet | Click to Show/Hide the Full List of Formulation(s): 10 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Glyceryl monostearate; Magnesium stearate; Acetone; Propylene glycol; Talc; Silicon dioxide; Alcohol; Carnauba wax; Cellulose acetate; Povidone, unspecified; White wax
|
|||||
Dosage Form | Delayed Release Oral Tablet | |||||
Company | Pharmacia and Upjohn Company | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Glyceryl monostearate | DIG Info | Prostate cancer LNCaP cells (IC50 > 100000 nM) | [2] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Diethyl phthalate; Talc; Croscarmellose sodium; Povidone k30; Carnauba wax; Cellacefate; Cellulose, microcrystalline; Starch, corn
|
|||||
Dosage Form | Delayed Release Oral Tablet | |||||
Company | Qualitest Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [5] | |||
Diethyl phthalate | DIG Info | Phosphodiesterase 4D (IC50 = 8.5 uM) | [6] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Stearic acid; Magnesium stearate; Sodium starch glycolate type a potato; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Actavis Pharma; AvPAK; Bryant Ranch Prepack; RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Stearic acid | DIG Info | Phosphodiesterase 3A (IC50 = 3.1 uM) | [6] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 4 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Stearic acid; Magnesium stearate; Sodium starch glycolate type a potato; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Stearic acid | DIG Info | Phosphodiesterase 3A (IC50 = 3.1 uM) | [6] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 5 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Acetone; Propylene glycol; Talc; Silicon dioxide; Alcohol; Carnauba wax; Povidone, unspecified; White wax
|
|||||
Dosage Form | Delayed Release Oral Tablet | |||||
Company | Greenstone | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 6 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Povidone; Silicon dioxide
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [7] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 7 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Talc; Croscarmellose sodium; Povidone k30; Cellulose, microcrystalline; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Aidarex Pharmaceuticals; Blenheim Phamacal; PD-Rx Pharmaceuticals; Qualitest Pharmaceuticals; RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 8 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Silicon dioxide; Povidone, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; Greenstone; Pharmacia and Upjohn Company | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 9 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Silicon dioxide; Povidones
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; Aphena Pharma Solutions-Tennessee; Avera McKennan Hospital; Kaiser Foundation Hospitals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Drug Formulation 10 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Sodium stearoyl lactylate; Sodium starch glycolate type a potato; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Preferred Pharamaceuticals; RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.